Skip to main content

Table 6 Basic information of included patients from our hospital diagnosed in 2003–2019 after PSM

From: Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma

Variables Total Early-onset GSRCC Late-onset GSRCC P value
Total 70 35 35  
Sex     1
Male 40 (57.14%) 20 (57.14%) 20 (57.14%)  
Female 30 (42.86%) 15 (42.86%) 15 (42.86%)  
Smoke     0.255
Never 54 (77.14%) 29 (82.86%) 25 (71.43%)  
Yes 16 (22.86%) 6 (17.14%) 10 (28.57%)  
Primary site     0.4
Cardia 3 (4.29%) 1 (2.85%) 2 (5.71%)  
Fundus 3 (4.29%) 1 (2.85%) 2 (5.71%)  
Antrum 42 (60%) 19 (54.28%) 23 (65.71%)  
Body 20 (28.57%) 13 (37.14%) 7 (20%)  
Overlappping/NOS 2 (2.86%) 1 (2.85%) 1 (2.85%)  
T stage     0.576
T1 8 (11.43%) 4 (11.43%) 4 (11.43%)  
T2 10 (14.28%) 5 (14.29%) 5 (14.29%)  
T3 10 (14.28%) 7 (20%) 3 (8.57%)  
T4 42 (60%) 19 (54.28%) 23 (65.71%)  
N stage     0.63
N0 139 (34.49%) 9 (25.71%) 8 (22.86%)  
N1 60 (14.89%) 2 (5.71%) 5 (14.29%)  
N2 19 (27.14%) 9 (25.71%) 10 (28.57%)  
N3 27 (72.86%) 15 (42.86%) 12 (34.29%)  
M stage     0.045
M0 59 (84.29%) 26 (74.29%) 33 (94.29%)  
M1 11 (15.71%) 9 (25.71%) 2 (5.71%)  
Lesion classification     0.689
Infiltration type 6 (8.57%) 4 (11.43%) 2 (5.71%)  
Ulcerative type 52 (74.29%) 25 (71.43%) 27 (77.14%)  
Protuberant type 12 (17.14%) 6 (17.14%) 6 (17.14%)  
Lymphatic vessel invasion     0.621
No 26 (37.14%) 12 (34.29%) 14 (40%)  
Yes 44 (62.86%) 23 (65.71%) 21(60%)  
Tumor size     0.203
≤ 2 cm 22 (31.43%) 8 (22.86%) 14 (40%)  
≤ 5 cm 33 (47.14%) 20 (57.14%) 13 (37.14%)  
 > 5 cm 15 (21.43%) 7 (20%) 8 (22.86%)  
Examined LNs     0.495
≤ 16 10 (14.29%) 6 (17.14%) 4 (11.43%)  
 > 16 60 (85.71%) 29 (82.86%) 31 (88.57%)  
Chemotherapy     1
No 38 (54.29%) 19 (54.29%) 19 (54.29%)  
Yes 32 (45.71%) 16 (45.71%) 16 (45.71%)  
\